ES2071250T3 - Nuevos compuestos del acido 4-amino-butirico, sus procedimientos de preparacion y los preparados farmaceuticos que los contienen. - Google Patents

Nuevos compuestos del acido 4-amino-butirico, sus procedimientos de preparacion y los preparados farmaceuticos que los contienen.

Info

Publication number
ES2071250T3
ES2071250T3 ES91401739T ES91401739T ES2071250T3 ES 2071250 T3 ES2071250 T3 ES 2071250T3 ES 91401739 T ES91401739 T ES 91401739T ES 91401739 T ES91401739 T ES 91401739T ES 2071250 T3 ES2071250 T3 ES 2071250T3
Authority
ES
Spain
Prior art keywords
radical
optionally substituted
atom
amino
nitrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91401739T
Other languages
English (en)
Inventor
Michel Debaert
Pascal Berthelot
Claude Vaccher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Servier de Medecine Translationnelle SARL
Original Assignee
ADIR SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ADIR SARL filed Critical ADIR SARL
Application granted granted Critical
Publication of ES2071250T3 publication Critical patent/ES2071250T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

COMPUESTOS DE FORMULA (I): EN LA QUE: R SUB 1 REPRESENTA UN GRUPO HIDROXI, AMINO, ALQUILAMINO O ALCOXI, O UN ATOMO DE HALOGENO, R SUB 2 REPRESENTA UN ATOMO DE HIDROGENO, UN RADICAL ALQUILO, UN RADICAL ACILO, O UN RADICAL ALCOXICARBONILO, R REPRESENTA: UN RADICAL DE FORMULA: EN LA QUE: X REPRESENTA UN ATOMO DE OXIGENO, DE AZUFRE, O UN GRUPO NH Y REPRESENTA UN ATOMO DE CARBONO, DE OXIGENO O DE NITROGENO, UN RADICAL DE FORMULA: EN LA QUE: Z REPRESENTA UN ATOMO DE OXIGENO, DE AZUFRE O UN GRUPO NH, T REPRESENTA UN ATOMO DE CARBONO O DE NITROGENO, UN RADICAL CICLOALQUILO, CICLOALQUILALQUILO, O DICICLOALQUILALQUILO EVENTUALMENTE SUSTITUIDO EN EL CICLO, UN RADICAL AROMATICO EVENTUALMENTE SUSTITUIDO Y QUE INCLUYE EN SU ESQUELETO CARBONADO 2 O 3 ATOMOS DE NITROGENO, UN RADICAL AROMATICO QUE INCLUYE EN SU ESQUELETO DE 1 A 3 ATOMOS DE NITROGENO Y ENLAZADO A UN CICLO BENCENICO, PUDIENDO ESTAR CADA UNO DE ESTOS 2 CICLOS EVENTUALMENTE SUSTITUIDO, O UN CICLO DE SIETE CIMAS, SATURADO O NO, QUE INCLUYE EN SUESQUELETO CARBONADO UNO O DOS ATOMOS DE NITROGENO EVENTUALMENTE ENLAZADO A UN CICLO BENCENICO EN EL CICLO NITROGENADO Y/O BENCENICO, POSEEN UNA ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES GABAB.
ES91401739T 1990-06-27 1991-06-27 Nuevos compuestos del acido 4-amino-butirico, sus procedimientos de preparacion y los preparados farmaceuticos que los contienen. Expired - Lifetime ES2071250T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9008093A FR2663934B1 (fr) 1990-06-27 1990-06-27 Nouveaux derives de l'acide 4 - amino butyrique, leur procede de preparation et les preparations pharmaceutiques qui les contiennent.

Publications (1)

Publication Number Publication Date
ES2071250T3 true ES2071250T3 (es) 1995-06-16

Family

ID=9398069

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91401739T Expired - Lifetime ES2071250T3 (es) 1990-06-27 1991-06-27 Nuevos compuestos del acido 4-amino-butirico, sus procedimientos de preparacion y los preparados farmaceuticos que los contienen.

Country Status (15)

Country Link
US (2) US5162364A (es)
EP (1) EP0463969B1 (es)
JP (1) JPH04243853A (es)
AT (1) ATE118213T1 (es)
AU (1) AU637242B2 (es)
CA (1) CA2045445A1 (es)
DE (1) DE69107250T2 (es)
DK (1) DK0463969T3 (es)
ES (1) ES2071250T3 (es)
FR (1) FR2663934B1 (es)
GR (1) GR3015796T3 (es)
IE (1) IE65593B1 (es)
OA (1) OA09373A (es)
PT (1) PT98100A (es)
ZA (1) ZA914969B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0656002T3 (da) * 1992-08-19 2000-11-27 Mcneilab Inc 3-Oxo-pyrido(1,2-a)benzimidazol-4-carboxyl- og 4-oxo-azepino(1,2-a)benzimidazol-5-carboxylderivater, som er anvendelige ved
US6489355B2 (en) * 1993-12-01 2002-12-03 Eli Lilly And Company Methods of inhibiting the effects of amyloidogenic proteins
FR2722192A1 (fr) * 1994-07-06 1996-01-12 Adir Nouveaux derives de l'acide 4-amino butyrique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB9906882D0 (en) * 1999-03-25 1999-05-19 Novartis Ag Organic compounds
SE9904508D0 (sv) 1999-12-09 1999-12-09 Astra Ab New compounds
SE9904507D0 (sv) 1999-12-09 1999-12-09 Astra Ab New compounds
US7319095B2 (en) 1999-12-09 2008-01-15 Astrazeneca Ab Use of GABAB receptor agonists
AR033779A1 (es) * 2001-06-08 2004-01-07 Astrazeneca Ab Compuestos utiles en la enfermedad de reflujo
EP2354120A1 (en) 2003-08-20 2011-08-10 XenoPort, Inc. Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
AU2004267100B2 (en) 2003-08-20 2010-10-07 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
PT1691811E (pt) 2003-12-11 2014-10-30 Sunovion Pharmaceuticals Inc Combinação de um sedativo e de um modulador de neurotransmissores e métodos para melhorar a qualidade do sono e tratamento da depressão
SE0401653D0 (sv) * 2004-06-24 2004-06-24 Astrazeneca Ab New compounds
EP2275096A3 (en) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
AU2006327314A1 (en) * 2005-12-23 2007-06-28 Astrazeneca Ab Pyrazoles for the treatment of GERD and IBS
AU2006327313A1 (en) * 2005-12-23 2007-06-28 Astrazeneca Ab Heterocyclic GABA-B modulators
AU2006327317B2 (en) 2005-12-23 2010-11-25 Astrazeneca Ab GABA-B receptor modulators
EP1968946A4 (en) * 2005-12-23 2010-05-05 Astrazeneca Ab IMIDAZOLE AS MODULATORS OF THE GABA B RECEPTOR
AU2006327315A1 (en) * 2005-12-23 2007-06-28 Astrazeneca Ab Imidazole derivatives for the treatment of gastrointestinal disorders
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20080262064A1 (en) * 2007-04-18 2008-10-23 Astrazeneca Ab Novel Compounds For The Treatment Of GI Disorders 682
CA2682301A1 (en) * 2007-04-18 2008-10-30 Astrazeneca Ab Xanthine compounds having a positive allosteric gabab receptor modulator effect
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2011113904A1 (en) 2010-03-17 2011-09-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Medicaments for the prevention and treatment of a disease associated with retinal ganglion cell degeneration
CN107050456B (zh) 2010-09-28 2022-08-12 加利福尼亚大学董事会 治疗代谢综合征相关疾病的gaba激动剂和治疗或预防i型糖尿病的gaba组合

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4940460B1 (es) * 1971-08-28 1974-11-02
US4328214A (en) * 1979-07-04 1982-05-04 Ciba-Geigy Corporation Cyclopeptides and pharmaceutical preparations thereof and also processes for their manufacture
ZA804008B (en) * 1979-07-04 1981-06-24 Ciba Geigy New cyclopeptides and pharmaceutical preparations thereof and also processes for their manufacture
US4581167A (en) * 1982-01-19 1986-04-08 Research Corporation Peptide synthesis and amino acid blocking agents
DE3241512A1 (de) * 1982-11-10 1984-05-10 Bayer Ag, 5090 Leverkusen Substituierte malonsaeurediamide, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel
JP2561478B2 (ja) * 1986-07-22 1996-12-11 武田薬品工業株式会社 グリセリン誘導体
GB8707412D0 (en) * 1987-03-27 1987-04-29 Fujisawa Pharmaceutical Co Peptide compounds
US5047540A (en) * 1987-12-17 1991-09-10 Shionogi & Co., Ltd. Lipid derivatives

Also Published As

Publication number Publication date
US5162364A (en) 1992-11-10
EP0463969A1 (fr) 1992-01-02
CA2045445A1 (fr) 1991-12-28
ATE118213T1 (de) 1995-02-15
AU637242B2 (en) 1993-05-20
PT98100A (pt) 1992-03-31
IE912224A1 (en) 1992-01-01
EP0463969B1 (fr) 1995-02-08
DE69107250T2 (de) 1995-09-21
DK0463969T3 (da) 1995-07-10
IE65593B1 (en) 1995-11-01
US5278166A (en) 1994-01-11
GR3015796T3 (en) 1995-07-31
ZA914969B (en) 1992-04-29
FR2663934A1 (fr) 1992-01-03
AU7929491A (en) 1992-01-02
FR2663934B1 (fr) 1994-06-03
JPH04243853A (ja) 1992-08-31
OA09373A (fr) 1992-09-15
DE69107250D1 (de) 1995-03-23

Similar Documents

Publication Publication Date Title
GR3015796T3 (en) New compounds of 4-aminobutyric acid, process for their preparation and pharmaceutical preparations containing them.
ES2105920B1 (es) Procedimiento para preparar compuestos de benzo-y piridopiridazinona y piridazinationa.
MX9206939A (es) Derivados de piperazina, procedimiento para su preparacion y composicion farmaceutica que los comprende
ES2058527T3 (es) Derivados de pirimidina condensados procedimiento y compuestos intermedios para su preparacion y composiciones farmaceuticas que los contienen.
ES2066875T3 (es) Aminoalquilindoles, procedimiento para su obtencion y preparados farmaceuticos que los contienen.
DK422583D0 (da) Fremgangsmade til fremstilling af diazobicyclo-(3,3,1)-nonaner
DK495683D0 (da) Beta-carboliner, fremgangsmade til fremstilling af samme og farmaceutisk praeparat indeholdende samme
NZ235658A (en) Anthraquinone derivatives containing at least one n'-disubstituted n'-oxide alkylamino substituent; preparatory processes and intermediates
ATE73790T1 (de) Amino 5,6,7,8tetrahydronaphtho(2,3b>furanderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
DE68928644D1 (de) Heterocyclische Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
DK0445026T3 (da) Aminomethylpiperidinderivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler indeholdende dem
DK611087D0 (da) Fremgangsmaade til fremstilling af mono-, di- og tricycliske aminosyrer samt mellemprodukter til denne fremgangsmaade og en fremgangsmaade til deres fremstilling
ZA853829B (en) Beta-lactam antibiotics,process for the preparation and their use as medicaments or growth-promoters in livestock rearing or as antioxidants
ES544417A0 (es) Procedimiento para preparar 8-alquiltio-2-piperazino-pirimido(5,4-d)pirimidinas.
ES2057802T3 (es) Nuevos derivados de 3-amino-cromano, procedimiento de preparacion y composiciones farmaceuticas que los contienen.
SE8006953L (sv) Heterocykliska foreningar
ES8702392A1 (es) Un procedimiento para preparar compuestos heterociclicos, en particular compuestos con un anillo de tiadiazinona
ES2063157T3 (es) Nuevos derivados del indol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES520486A0 (es) Procedimiento para la preparacion de fenoleteres biciclicos.
DK469285D0 (da) Thiadiazolderivater, der indvirker paa centralnervesystemet, fremgangsmaade til fremstilling deraf og midler indeholdende derivaterne
DK356287D0 (da) 2,6-piperazindionderivater, fremgangsmaade til fremstilling deraf og farmaceutiske praeparater indeholdende disse
DK433383A (da) Fremgangsmaade til fremstilling af vinylcarbamater og hidtil ukendte vinylcarbamater
ES476232A1 (es) Procedimiento para la obtencion de derivados del fosfonilu- reidobenceno.
ATE53839T1 (de) 2,3-dihydro-3-phenyl-benzofuran-2-onacetamidderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
DK423983A (da) Fremgangsmaade til fremstilling af nitrosoforbindelser

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 463969

Country of ref document: ES